Summary:
TTK Healthcare shares surged 20% ahead of a November 20 board meeting to consider bonus redeemable preference shares. Terms remain undisclosed, while Q2 reported profit was boosted by a brand-sale gain and underlying operating profitability remained weak.
The November 20 meeting will decide terms of non-convertible redeemable preference shares for equity holders. Core operations remain under pressure after the recent brand sale.
TTK Healthcare shares jumped as much as 20% on November 17 after the company told exchanges its board would meet on November 20 to consider a scheme of arrangement for issuing non-convertible redeemable preference shares by way of bonus to existing equity shareholders.
The stock hit an intraday high near ₹1,106–1,110 from the previous close of about ₹926. That move took it closer to the September 2026 peak of ₹1,250, well above the March low of ₹735. Volume spiked several times normal levels.
In a November 16 filing under Regulation 29 of the SEBI LODR Regulations, the company said the board would consider and approve the scheme under Section 230 of the Companies Act, 2013. The scheme relates to issuance of Non-Convertible Redeemable Preference Shares (NCRPS) by way of bonus to equity shareholders.
No ratio, face value, coupon rate, tenure or redemption terms have been disclosed. The trading window for designated persons closed from November 16 to November 22. Those details, if the board approves the scheme, will come later.
20% Surge Prices in Preference-Share Cash Return Before Any Terms Are Known
The market has already capitalised an expectation of a cash-return instrument. Preference shares that are non-convertible and redeemable sit between debt and equity. They typically carry a fixed coupon and get repaid at a fixed date or event. For equity holders they can function as a cash return vehicle without diluting ordinary share capital.
Core Pre-Exceptional Profit Fell Roughly 7–8% Once the ₹248 Cr Brand-Sale Gain Is Removed
The rally comes weeks after a sharp post-results sell-off. In Q2 FY27 (quarter ended September 2026) revenue from operations rose 14.6% year-on-year to ₹233.4 crore. Reported net profit surged to ₹223 crore from ₹20.4 crore a year earlier.
Almost the entire profit jump came from a ₹248.2 crore exceptional gain on the sale of the EVA personal-care and GoodHome home-care brands and related assets to Wipro Enterprises. The sale completed on September 4 for a headline consideration of ₹256 crore plus GST. Strip out the one-off and core pre-exceptional profit before tax was down roughly 7–8% year-on-year.
EBITDA fell 29.7% to ₹3.7 crore; the operating margin compressed to 1.6% from 2.6%. Consumer products swung to a small loss once the divested brands stopped contributing mid-quarter. Protective devices (Skore and related) narrowed losses sharply. Foods remained a bright spot.
The balance sheet strengthened. Cash and bank balances rose substantially after the brand sale. The company is essentially debt-free. Promoters hold about 74.6% of the roughly 1.413 crore equity shares outstanding.
NCRPS Bonus Returns Brand-Sale Cash Without Diluting the 74.6% Promoter Stake
TTK Healthcare has not announced an equity bonus in recent history. A preference-share bonus is a different animal. It lets the company distribute value from the cash raised by the brand sale without increasing the number of ordinary shares or diluting promoter control.
Investors will watch three things on November 20 and in the subsequent scheme documents: the entitlement ratio, the coupon and redemption schedule, and whether the instrument is funded from the proceeds of the EVA/GoodHome sale or from other reserves. A meaningful coupon with a clear redemption path would be closer to a special dividend than to a classic equity bonus.
November 20 Ratio, Coupon and Redemption Terms Will Decide Whether the 20% Premium Holds
The market is currently pricing the stock at roughly book value or a modest premium, depending on the exact closing price after today’s move. Trailing earnings are inflated by the one-off gain; the more relevant multiple is on core operating profit, which remains thin.
The 20% move prices in an expectation that the scheme will return cash to shareholders on attractive terms. Whether that expectation is met depends entirely on the numbers the board puts on the table on November 20.
• Board outcome on November 20: ratio, coupon, tenure and redemption terms of the NCRPS.
• Any guidance on use of the brand-sale proceeds beyond the preference-share distribution.
• Core margin trajectory in H2 FY27 after the consumer-products portfolio has fully adjusted to the EVA and GoodHome exit.
• Progress in protective devices and foods, the two segments that have shown clearer operating improvement.
Until then the stock is trading on a headline, not on a defined instrument.
Key Numbers After the 20% Move and Q2 Exceptional Gain
| Metric | Detail |
| Previous close (16 Nov) | ≈ ₹926 |
| Intraday high (17 Nov) | ₹1,106–1,110 |
| 52-week range | ₹735–₹1,250 |
| Q2 FY27 revenue | ₹233.4 crore (+14.6% YoY) |
| Q2 FY27 reported PAT | ₹223 crore (exceptional gain driven) |
| Brand sale consideration | ₹256 crore + GST |
| Promoter holding | ≈ 74.6% |














